Omada Health Inc

OMDA has decisively broken near-term support on high volume, trading below its short-term EMAs in an extreme oversold context. While mean-reversion conditions permit a tactical long bias, the lack of reversal confirmation and sustained downward momentum argue for deferred execution. Focus on potential buy zones near the 17–18 area or after price stabilizes above the EMA cluster.

• ↑Q2 2026 revenue reached $88M, up 43% YoY.
• ↑Gross margin expanded 700bps to 73% year-over-year.
• ↓Earnings yield negative, implying stretched valuation.